As already mentioned, ibrutinib resistance in MCL was also linked to increased expression of MYC and OxPhos gene signatures and, once again, these ibrutinib‐resistant cells were sensitive to OxPhos inhibition with IACS‐010759 [101]. Here, MYC is linked to mantle cell lymphoma.